奥沙利铂或顺铂联合足叶乙甙治疗老年广泛期小细胞肺癌的随机对照临床研究

背景与目的足叶乙甙（VP-16）联合顺铂（DDP）是广泛期小细胞肺癌（small cell lung cancer,SCLC）一线联合化疗中最常用的方案,但顺铂的恶心呕吐毒副反应影响患者的生存质量。本研究拟比较足叶乙甙联合奥沙利铂或顺铂一线治疗老年广泛期SCLC的疗效及毒副反应。方法未经抗肿瘤治疗的老年广泛期SCLC患者71例,随机分成两组,EO组（足叶乙甙80mg/m2第1-5天＋奥沙利铂130mg/m2第1天静脉滴注,每21天重复）35例,EP组（足叶乙甙80mg/m2第1-5天＋顺铂25mg/m2第1-3天静脉滴注,每21天重复）36例,至少治疗2周期以后评价疗效及不良反应。结果 EO组...

Full description

Saved in:
Bibliographic Details
Published in中国肺癌杂志 Vol. 16; no. 1; pp. 20 - 24
Main Author 蒲丹 侯梅 李之曦 曾晓梅
Format Journal Article
LanguageChinese
Published 四川大学华西医院肿瘤中心,成都,610041 2013
Subjects
奥沙利铂
小细胞肺癌
老年
足叶乙甙
顺铂
奥沙利铂
小细胞肺癌
顺铂
老年
足叶乙甙
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2013.01.04

Cover

Abstract 背景与目的足叶乙甙（VP-16）联合顺铂（DDP）是广泛期小细胞肺癌（small cell lung cancer,SCLC）一线联合化疗中最常用的方案,但顺铂的恶心呕吐毒副反应影响患者的生存质量。本研究拟比较足叶乙甙联合奥沙利铂或顺铂一线治疗老年广泛期SCLC的疗效及毒副反应。方法未经抗肿瘤治疗的老年广泛期SCLC患者71例,随机分成两组,EO组（足叶乙甙80mg/m2第1-5天＋奥沙利铂130mg/m2第1天静脉滴注,每21天重复）35例,EP组（足叶乙甙80mg/m2第1-5天＋顺铂25mg/m2第1-3天静脉滴注,每21天重复）36例,至少治疗2周期以后评价疗效及不良反应。结果 EO组与EP组相比,治疗缓解率（55.9%vs54.3%,P=0.894）,疾病控制率（82.4%vs77.1%,P=0.591）,中位无进展生存期（5.5个月vs4.7个月,P=0.638）,中位生存时间（10.5个月vs9.1个月,P=0.862）差异均无统计学意义;毒副反应方面,EO组恶心呕吐等消化道反应发生率低于EP组（65.7%vs97.2%,P=0.001）,但I级-II级神经毒性发生率高于EP组（74.3%vs11.1%,P〈0.001）。结论足叶乙甙联合奥沙利铂或顺铂两种方案用于一线治疗老年广泛期SCLC的疗效相当,但EO组患者耐受性相对较好。
AbstractList 背景与目的足叶乙甙（VP-16）联合顺铂（DDP）是广泛期小细胞肺癌（small cell lung cancer,SCLC）一线联合化疗中最常用的方案,但顺铂的恶心呕吐毒副反应影响患者的生存质量。本研究拟比较足叶乙甙联合奥沙利铂或顺铂一线治疗老年广泛期SCLC的疗效及毒副反应。方法未经抗肿瘤治疗的老年广泛期SCLC患者71例,随机分成两组,EO组（足叶乙甙80mg/m2第1-5天＋奥沙利铂130mg/m2第1天静脉滴注,每21天重复）35例,EP组（足叶乙甙80mg/m2第1-5天＋顺铂25mg/m2第1-3天静脉滴注,每21天重复）36例,至少治疗2周期以后评价疗效及不良反应。结果 EO组与EP组相比,治疗缓解率（55.9%vs54.3%,P=0.894）,疾病控制率（82.4%vs77.1%,P=0.591）,中位无进展生存期（5.5个月vs4.7个月,P=0.638）,中位生存时间（10.5个月vs9.1个月,P=0.862）差异均无统计学意义;毒副反应方面,EO组恶心呕吐等消化道反应发生率低于EP组（65.7%vs97.2%,P=0.001）,但I级-II级神经毒性发生率高于EP组（74.3%vs11.1%,P〈0.001）。结论足叶乙甙联合奥沙利铂或顺铂两种方案用于一线治疗老年广泛期SCLC的疗效相当,但EO组患者耐受性相对较好。
R734.2; 背景与目的 足叶乙甙(VP-16)联合顺铂(DDP)是广泛期小细胞肺癌(small cell lung cancer,SCLC)一线联合化疗中最常用的方案,但顺铂的恶心呕吐毒副反应影响患者的生存质量.本研究拟比较足叶乙甙联合奥沙利铂或顺铂一线治疗老年广泛期SCLC的疗效及毒副反应.方法 未经抗肿瘤治疗的老年广泛期SCLC患者71例,随机分成两组,EO组(足叶乙甙80 mg/m2第1-5天+奥沙利铂130 mg/m2第1天静脉滴注,每21天重复)35例,EP组(足叶乙甙80 mg/m2第1-5天+顺铂25 mg/m2第1-3天静脉滴注,每21天重复)36例,至少治疗2周期以后评价疗效及不良反应.结果 EO组与EP组相比,治疗缓解率(55.9％ vs 54.3％,P=0.894),疾病控制率(82.4％ vs 77.1％,P=0.591),中位无进展生存期(5.5个月vs 4.7个月,P=0.638),中位生存时间(10.5个月vs 9.1个月,P=0.862)差异均无统计学意义；毒副反应方面,EO组恶心呕吐等消化道反应发生率低于EP组(65.7％vs 97.2％,P=0.001),但Ⅰ级-Ⅱ级神经毒性发生率高于EP组(74.3％ vs 11.1％,P＜0.001).结论 足叶乙甙联合奥沙利铂或顺铂两种方案用于一线治疗老年广泛期SCLC的疗效相当,但EO组患者耐受性相对较好.
Author 蒲丹 侯梅 李之曦 曾晓梅
AuthorAffiliation 四川大学华西医院肿瘤中心,成都610041
AuthorAffiliation_xml – name: 四川大学华西医院肿瘤中心,成都,610041
Author_FL Zhixi LI
Dan PU
Mei HOU
Xiaomei ZENG
Author_FL_xml – sequence: 1
  fullname: Dan PU
– sequence: 2
  fullname: Mei HOU
– sequence: 3
  fullname: Zhixi LI
– sequence: 4
  fullname: Xiaomei ZENG
Author_xml – sequence: 1
  fullname: 蒲丹 侯梅 李之曦 曾晓梅
BookMark eNo1kEtLAlEAhS9hkFo_Ilq0muneude5M8uQXiC0cS_XeZhSYzlE5CrtgURgkBhj0mMh4apQkWZc9Ge8M-O_aMJancPh4xw4CRCzypYBwBqCIqZU3SiJRdu2RAShKmCCVFGCCIsQiZAsgDhSVVWQkUJjkf9HlkDCtksQypKKSRyYvNfzBw5v9GcPdb_Rnr15kQlrLX7fCMdD3hxPXSdoOf5gErQfw4sad0fc_faHT373hX82g8lNePkc1r3AuQs6V7NO0-96_MMNrt-nXyPu3QavraA_XgaLJju0jZU_TYLs9lY2vStk9nf20psZQUspRCB5SgyCKCG6RGnelJGkQFXXZCbJehQYEKZ0wyAao1RjpgJNpumGnIdSnkJsIpwE6_PaM2aZzCrkSuXTihUN5qoFk1Wrv_fA6AoSkatzUjsoW4WTYsQeV4pHrHKeI0SOhjHEP1tsjec
ClassificationCodes R734.2
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3779/j.issn.1009-3419.2013.01.04
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate A Randomized Controlled Study of Chemotherapy： Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment of Extensive-stage Small Cell Lung Cancer in Elderly Patients
DocumentTitle_FL A Randomized Controlled Study of Chemotherapy:Etoposide Combined with Oxaliplatin or Cisplatin Regimens in the Treatment of Extensive-stage Small Cell Lung Cancer in Elderly Patients
EISSN 1999-6187
EndPage 24
ExternalDocumentID zgfazz201301004
44661230
GroupedDBID ---
-05
04C
29R
2B.
2C~
2RA
2WC
3V.
5GY
5VS
6PF
92F
92I
92L
AAWTL
ABUWG
ACGFS
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVBZV
C1A
CCEZO
CCPQU
CIEJG
CQIGP
CW9
DIK
E3Z
EBD
EIHBH
EMOBN
EOJEC
F5P
GROUPED_DOAJ
HYE
IPNFZ
KQ8
KWQ
OBODZ
OK1
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
PGMZT
PHGZM
PHGZT
PMFND
PSX
ID FETCH-LOGICAL-c584-4b74e41744d277bf612809dc6a26d77be005dee4ca77caf80facde6b02b703f13
ISSN 1009-3419
IngestDate Thu May 29 03:56:17 EDT 2025
Wed Feb 14 10:43:39 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords 奥沙利铂
小细胞肺癌
顺铂
老年
足叶乙甙
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c584-4b74e41744d277bf612809dc6a26d77be005dee4ca77caf80facde6b02b703f13
Notes Etoposide; Oxaliplatin; Cisplatin; Small cell lung cancer; The elderly
Dan PU, Mei HOU, Zhixi LI, Xiaomei ZENG Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China
[ Abstract ] Background and objective Etoposide combined cisplatin （EP） is the most commonly-used first-line treatment combination chemotherapy regimen in the treatment of extensive-stage small cell lung cancer （SCLC）, ＂Ihe side- effects of cisplatin, such as nausea and vomiting, influence patients＇ quality of life.This study aims to compare the efficacy and toxicities between etoposide plus oxaliplatin （EO） and etoposide plus cisplatin （EP） regimens as first-line chemotherapy for elderly patients with SCLC. Methods Seventy-one old, extensive-stage SCLC patients
12-1395/R
PageCount 5
ParticipantIDs wanfang_journals_zgfazz201301004
chongqing_primary_44661230
PublicationCentury 2000
PublicationDate 2013
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – year: 2013
  text: 2013
PublicationDecade 2010
PublicationTitle 中国肺癌杂志
PublicationTitleAlternate Chinese Journal of Lung Cancer
PublicationTitle_FL Chinese Journal of Lung Cancer
PublicationYear 2013
Publisher 四川大学华西医院肿瘤中心,成都,610041
Publisher_xml – name: 四川大学华西医院肿瘤中心,成都,610041
SSID ssj0062934
ssib002262905
ssib044765436
ssib001103766
ssib038074678
ssib051369142
Score 1.9586228
Snippet 背景与目的足叶乙甙（VP-16）联合顺铂（DDP）是广泛期小细胞肺癌（small cell lung cancer,SCLC）一线联合化疗中最常用的方案,但顺铂的恶心呕吐毒副反应影响患者的生存质...
R734.2; 背景与目的 足叶乙甙(VP-16)联合顺铂(DDP)是广泛期小细胞肺癌(small cell lung cancer,SCLC)一线联合化疗中最常用的方案,但顺铂的恶心呕吐毒副反应影响患者的生存...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 20
SubjectTerms 奥沙利铂
小细胞肺癌
老年
足叶乙甙
顺铂
Title 奥沙利铂或顺铂联合足叶乙甙治疗老年广泛期小细胞肺癌的随机对照临床研究
URI http://lib.cqvip.com/qk/91098A/201301/44661230.html
https://d.wanfangdata.com.cn/periodical/zgfazz201301004
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: KQ8
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DOA
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib044765436
  issn: 1009-3419
  databaseCode: M~E
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: East & South Asia Database
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BVBZV
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eastsouthasia
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BENPR
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LShxBsDEKkkvIk2gSEZI-yZp59uM4o7NIQAnBgLdl56WnNQ-97CmaBxICBiKGNZLHQYKnBBXJ6iE_4-ysf5GqntlxSUSSwDIUNVXV1VU7XdUz3dWE3OF2aMRWUC3xKBBYVNsuCRHIki31MOCC-VV1TOfkFJt4aN2bsWd6zvldq5YWF_zRoH7qvpL_8SrgwK-4S_YfPFsIBQTA4F-4gofh-lc-pp5NHfXzGHUNKiVihKAOAJJKkwoDbwFGMsQ4OnWdrlsCEkkqLeSSGpIBxgVRppJTRtizqCuVZI6UCKi2XFdhGJVcydFQFHABsWt1gLIiNql0EZBjVJbVLQ2FAzsIEUyxA42nAENpyLEhMaYAhwpL6ewoLiUHaaDjZWwFaATAXKkqOq0DsZLjaKqDHG3isu5cPKd3xlX3XeqOn6YANDeubGVjd2QRtpFWGmiJvFk5oiAPtQIuxwCtRjr8Xm5HkRnCpQ4bySHgQED5pMPX_S4m20SbBw78yIS18bK4muGwwgPT84SiE23YH09VHjq0riQk21f-e3jD4pAqvKH40aJJXKBoquKz1klUL9Za4gd7SE-0c6TP4AD2kj7Xm7r_4CRpxq2i3ZN4gxnyJArgiQQQTYtR2rI47kcu6G3dZFK3iqJtwJyt5eio109u57rfPUNzrG0yN1-bfQwZm9pAV4urtdmuXG_6IrmQT9KGneyJu0R66nOXSf9kvgzlComTra3WTiNZ2T5-t9xaWT_-cgBAe2ktebvS3t9NVvePmo10rdHaOUzX37efLSXNvaT5s7X7obX5Kfm-mh6-aj__2F4-SBtv0o0Xxxurrc2D5Fszffn16MdecvA6_byWbu9fJdNlb3psopQfWFIKII8vWT63Igum-FZocO7HYHahyTBgVYOFgIgg4oVRBCMj50E1FlpcDcKI-ZrhQ9yNdfMa6a3N16LrZJiHNk7mWRzZzJKxIQNp6lHgs1D3TcnYABksrFV5lNWlqXQ8PUCGc_NV8sHqaaU-G1frdTS3hjUiB8_iv0HOG-rQF3zReJP0LjxZjG5B6r3gD-X_nSH16uoX1Ge1rg
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%A5%A5%E6%B2%99%E5%88%A9%E9%93%82%E6%88%96%E9%A1%BA%E9%93%82%E8%81%94%E5%90%88%E8%B6%B3%E5%8F%B6%E4%B9%99%E7%94%99%E6%B2%BB%E7%96%97%E8%80%81%E5%B9%B4%E5%B9%BF%E6%B3%9B%E6%9C%9F%E5%B0%8F%E7%BB%86%E8%83%9E%E8%82%BA%E7%99%8C%E7%9A%84%E9%9A%8F%E6%9C%BA%E5%AF%B9%E7%85%A7%E4%B8%B4%E5%BA%8A%E7%A0%94%E7%A9%B6&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%82%BA%E7%99%8C%E6%9D%82%E5%BF%97&rft.au=%E8%92%B2%E4%B8%B9+%E4%BE%AF%E6%A2%85+%E6%9D%8E%E4%B9%8B%E6%9B%A6+%E6%9B%BE%E6%99%93%E6%A2%85&rft.date=2013&rft.issn=1009-3419&rft.eissn=1999-6187&rft.volume=16&rft.issue=1&rft.spage=20&rft.epage=24&rft_id=info:doi/10.3779%2Fj.issn.1009-3419.2013.01.04&rft.externalDocID=44661230
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91098A%2F91098A.jpg
http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgfazz%2Fzgfazz.jpg